MA-PEG4-VA-PBD - CAS 1342820-68-1 Catalog number: BADC-00738

MA-PEG4-VA-PBD is a versatile compound primarily used in the development of targeted cancer therapies, particularly antibody-drug conjugates (ADCs). The maleimide (MA) group allows for efficient conjugation to biomolecules containing thiol groups, such as antibodies or peptides. The PEG4 (polyethylene glycol) spacer enhances the solubility and stability of the conjugate, improving its pharmacokinetics. The VA (valine-alanine) linker is designed to be cleaved in the intracellular environment, ensuring that the cytotoxic payload, PBD (Pyrrolo[2,1-c][1,4]benzodiazepine), is released inside the target cell. PBD is a potent DNA crosslinker that interferes with DNA replication and transcription, leading to apoptosis. This combination of components makes MA-PEG4-VA-PBD a promising candidate for targeted drug delivery in oncology.

One of the main applications of MA-PEG4-VA-PBD is in the development of ADCs for targeted cancer therapy. By attaching the potent cytotoxic agent PBD to an antibody via the maleimide-PEG4-VA linker system, the drug is selectively delivered to cancer cells that express specific surface antigens. The linker is designed to be cleaved once the ADC enters the target cell, allowing for the release of PBD inside the cell. Upon release, PBD crosslinks DNA, disrupting the normal function of the DNA helix and leading to cell cycle arrest and programmed cell death. This targeted delivery system significantly improves the therapeutic index of the drug by minimizing systemic toxicity and maximizing the cytotoxic effect on tumor cells.

MA-PEG4-VA-PBD also plays a critical role in drug resistance studies and the optimization of ADC design. Researchers can utilize this conjugate to investigate how tumor cells develop resistance to chemotherapeutic agents and identify strategies to overcome this resistance. By modifying the linker, payload, or antibody targeting moiety, new ADC formulations can be tested for improved efficacy. This could lead to the development of ADCs with enhanced potency or the ability to bypass mechanisms of drug resistance, providing more effective treatments for resistant cancer strains.

Beyond oncology, MA-PEG4-VA-PBD may have potential applications in the treatment of other diseases where targeted therapy is beneficial. The flexibility of the maleimide-PEG4-VA linker system allows for the attachment of various targeting molecules, making it adaptable for the treatment of infectious diseases, autoimmune disorders, or inflammatory conditions. By coupling MA-PEG4-VA-PBD to peptides or antibodies that recognize specific disease markers, this conjugate could provide a new approach to the targeted delivery of cytotoxic agents in non-cancerous applications, expanding its therapeutic potential.